Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
8) Management of stress urinary incontinence in adult women.
Off-label uses include:
1) Management of chemotherapy-induced peripheral neuropathy.
2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Evaluation of the Effects of Duloxetine on Norepinephrine
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT00414323
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
Duloxetine Versus Placebo for Osteoarthritis Knee Pain
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 231
- Registration Number
- NCT00408421
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania
Duloxetine Versus Placebo in Chronic Low Back Pain
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2009-12-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 404
- Registration Number
- NCT00408876
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tampa, Florida, United States
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00401258
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 6
- Registration Number
- NCT00398632
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Treatment With Duloxetine for OCD Patients
- Conditions
- OCD
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2008-01-31
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00399022
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel
Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 14
- Registration Number
- NCT00388414
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers
- Conditions
- Hyperalgesia
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00387413
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT00375973
- Locations
- 🇺🇸
Women's Health Research Program, Cincinnati, Ohio, United States
Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep
- Conditions
- Diabetes MellitusPeripheral Neuropathies
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2009-11-17
- Lead Sponsor
- University of Surrey
- Target Recruit Count
- 90
- Registration Number
- NCT00370656
- Locations
- 🇬🇧
Poole General Hospital, Poole, Dorset, United Kingdom
🇬🇧Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧University of Surrey Clinical Research Centre, Guildford, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.